{
}
Merck shares, which hit a low of EUR 132.80 on February 12, 2025, have since rebounded to EUR 142.45 by March 7, 2025, and are currently trading around EUR 122. Analysts from J.P. Morgan and UBS project target prices of EUR 190.00 and EUR 180.00, respectively, with key resistance levels identified at EUR 190.70. Support levels are noted at EUR 117.18, EUR 107.53, and EUR 101.57.
Goldman Sachs has lowered its price target for Merck & Co., Inc. to $99 from $103 while maintaining a Buy rating. Merck specializes in therapeutic products and vaccines, with net sales primarily from pharmaceuticals (67%), vaccines (22.1%), and animal health products (9.4%). Geographically, sales are led by the United States (47.4%), followed by Europe/Middle East/Africa (22%) and China (11.3%).
UBS has maintained a Buy rating on Merck with a price target of $105, despite concerns over Gardasil sales projections, which UBS estimates at $1.3 billion for Q1, below the consensus of $1.4 billion. Merck's strong fundamentals include a 77% gross profit margin and a robust EBITDA of $29.1 billion. Upcoming events, such as the reassessment of Gardasil demand in China and the Phase 3 CORALreef study results, are seen as potential inflection points for investor interest.
UBS analyst Trung Huynh has reaffirmed a Buy rating on Merck (NYSE: MRK) with a price target of $105.00. The analyst noted positive sentiment surrounding the company, indicating confidence in its future performance.
UBS warns that the healthcare sector remains vulnerable despite President Trump's recent announcements, which did not initially target the pharmaceutical industry with tariffs. Trump indicated that pharmaceutical companies must return to the U.S. or face significant taxes, suggesting potential future tariffs or tax reforms. UBS identifies Abbvie and Merck as likely beneficiaries of these developments.
The Goldman Sachs Group reported a strong quarterly performance with earnings per share of $11.95, exceeding estimates, and a revenue of $13.87 billion, up 22.5% year-over-year. Despite a Hold rating from analysts, several firms have adjusted their price targets, with an average target of $590.60. The company also announced a quarterly dividend of $3.00, yielding 2.21%.
Summit Securities Group LLC acquired a new stake in The Goldman Sachs Group, purchasing 14,600 shares valued at approximately $8.36 million, making it the firm's 7th largest position. Insider trading saw significant sales, with Kathryn H. Ruemmler selling 7,498 shares for nearly $4.76 million. The company reported strong quarterly earnings, beating estimates with $11.95 EPS and a revenue of $13.87 billion, reflecting a 22.5% year-over-year increase.
Goldman Sachs has raised its price target for AstraZeneca shares to £151.30, maintaining a Conviction Buy rating, citing an 18% revenue growth and potential in the oral PCSK9 inhibitor market with AZD0780. The anticipated Phase 2 PURSUIT trial data, due on March 31, 2025, is expected to significantly impact the competitive landscape. AstraZeneca is also investing $2.5 billion in a new R&D center in Beijing, enhancing its presence in China and focusing on early-stage research and clinical development.
The High Potency Active Pharmaceutical Ingredients Market is experiencing significant growth, driven by increased demand, technological advancements, and a broadening customer base. A comprehensive report provides insights into market trends, competitive landscape, and future opportunities, highlighting key players such as Lonza and Novartis. The analysis covers various segments, production technologies, and applications, offering a detailed outlook on the industry's trajectory through 2032.
Pfizer's shares have shown mixed performance recently, with a slight decline to EUR 24.50 on February 13, 2025, following a positive trading day that saw a rise to EUR 25.22. The company reported a 7% increase in annual revenue to $63.6 billion for 2024, driven by strong sales of Covid-19 drugs and other key products, while maintaining a shareholder-friendly dividend policy. Analysts have adjusted their price targets, with ratings ranging from "Buy" to "Neutral," reflecting a cautious but optimistic outlook for 2025.
Merck & Co., Inc.
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Merck shares show potential for significant upside according to analysts
17:47 30.04.2025
goldman sachs lowers merck price target while maintaining buy rating
15:54 25.04.2025
ubs maintains buy rating for merck with price target of 105 dollars
16:43 03.04.2025
ubs maintains buy rating and price target for merck
15:45 03.04.2025
pharmaceutical sector faces uncertainty amid potential tariffs and tax changes
10:50 03.04.2025
goldman sachs group reports strong earnings but analysts suggest better investment options
12:40 31.03.2025
goldman sachs reports strong quarterly earnings and dividend announcement
Merck & Co., Inc.
Morgan Stanley
Wells Fargo & Company
UBS Group AG
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Citigroup Inc.
USA
Show more
12:06 30.03.2025
Goldman Sachs raises AstraZeneca target amid promising drug development and expansion
08:50 28.03.2025
high potency active pharmaceutical ingredients market trends and future growth prospects
Merck & Co., Inc.
Roche Diagnostics AG
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd
BASF AG
Novartis International AG
Lonza Group AG
Bristol-Myers Squibb Co
Cambrex Corporation
Seqens
Pfizer Inc.
Sanofi Aventis SA
Bayer AG
CARBOGEN AMCIS AG
Alice Mutum
Viju Shah
Show more
10:02 26.03.2025
Pfizer reports strong fourth quarter results and maintains positive 2025 outlook
14:10 13.02.2025
Trending
Subcategory
Corporate News
Industry Trends
Venture Capital Investments
Startups & Entrepreneurship
Fintech Startups
Funding Rounds & Investments
AI Innovations
Emerging Startups
AI Applications
Government Economic Policies
Cryptocurrency Trends
Economic Indicators
Retail and Consumer Goods
Global Trade Developments
Crypto Policies and Governance
Stock Market Updates
Crypto Adoption and Integration
Private Equity Deals
Industry Mergers & Acquisitions
Product Launches
Countries:
Companies:
Google Inc.
Nvidia Corporation
Microsoft Corporation Corp.
Google LLC
Joby Aviation Inc.
Toyota Motor Corporation
Intel Corporation
Scalable Capital GmbH
Globalfoundries Inc.
Zero Networks Ltd.
Xiaomi Corporation
Li Auto Inc.
Luxshare Precision Industry Co. Ltd.
Wens Foodstuff Group Co. Ltd.
Constellation Energy Group Inc.
Advanced Micro Devices Inc.
Apple Inc.
Deutsche Telekom AG
Kamari Pharma Ltd.
Miniso Group Holding Ltd.
Currencies:
United States Dollar
Euro
Chinese Yuan
Indian Rupee
South Korean Won
Japanese Yen
Qatari Riyal
Offshore Chinese Yuan
United Arab Emirates Dirham
People: